Explain this page
Arphra AIPlain-English read on Henry Schein, Inc.’s valuationOverview
Discounted cash flow
Income / accounting-based
Multiples & assets
Scenario
Toolbox
Weighted blend
$188.23
+145.80% vs spot
Strong Buy
Spot price
$76.58
Mkt cap $8.72B
subtle cardAnalyst PT consensus
$86.43
+12.86% vs spot
subtle cardMethods covered
15 / 16
14 in blend
subtle cardFootball field
HSIC · fair-value range by method
Method comparison
HSIC · fair value by valuation framework
| Method | Category | Fair value | Range | vs spot | Weight | Driver | Conf. |
|---|---|---|---|---|---|---|---|
| DCF · FCFF | dcf | $319.51 | $212.72 – $508.91 | +317.23% | 23.7% | WACC 6.0%, g₀=25.0%, gₗ=2.0% | high |
| DCF · FCFE | dcf | $174.19 | $131.31 – $238.06 | +127.46% | 17.8% | kₑ 8.1%, g₀=25.0%, gₗ=2.0% | high |
| Residual income | income | $43.45 | $38.24 – $48.67 | -43.26% | 11.8% | BV 43.28, ROE 8.3% → kₑ | high |
| EVA / MVA | income | $269.06 | $236.78 – $301.35 | +251.35% | 8.3% | IC 8.3B, WACC 6.0% | high |
| P/E · sector | multiple | $71.94 | $63.31 – $80.57 | -6.06% | 14.2% | EPS 3.27 × peer P/E 22.0 | med |
| P/S · sector | multiple | $476.05 | $404.65 – $547.46 | +521.64% | 3.6% | Rev/sh 119.01 × peer P/S 4.00 | med |
| EV / EBITDA | multiple | $104.34 | $91.82 – $116.87 | +36.26% | 11.8% | EBITDA × peer 15.0× − ND 3.5B | high |
| EV / EBIT | multiple | $91.29 | $77.60 – $104.98 | +19.21% | 2.4% | EBIT × peer 18.0× − ND | med |
| EV / Sales | multiple | $372.77 | $316.86 – $428.69 | +386.77% | 2.4% | Sales × peer 3.40× − ND | med |
| PEG-anchored | multiple | $130.80 | $111.18 – $150.42 | +70.80% | 1.2% | PEG=1, fwd EPS g 63.5% | med |
| Earnings power | intrinsic | $56.49 | $49.71 – $63.27 | -26.23% | 0.6% | NOPAT / WACC, no growth | med |
| Graham revised | intrinsic | $156.46 | $132.99 – $179.93 | +104.31% | 0.6% | EPS×(8.5+2g)·4.4/Y | low |
| Lynch P/E=g | intrinsic | $81.75 | $69.49 – $94.01 | +6.75% | 0.6% | PE = g (25.0) | low |
| Book NAV | asset | $43.28 | $41.11 – $45.44 | -43.49% | 1.2% | (Assets − Liabilities) / Shares | high |
| Liquidation | asset | $13.33 | $11.33 – $15.33 | -82.60% | — | Cash 100% + non-cash 70% − Liab. | low |
| Reverse DCF | reverse | — | — | — | — | Implied g -2.2% · Pessimistic — market pricing decline | high |
Cost-of-capital build-up
CAPM cost of equity, after-tax cost of debt, WACC. Risk-free as of 2026-05-12.
| Risk-free rate (US 10y Treasury)rf | 4.46% |
| Equity beta (0.82)β | × 0.82 |
| Equity risk premiumERP | 4.46% |
| Cost of equity (CAPM)kₑ | 8.13% |
| Pre-tax cost of debtkd | 4.07% |
| Effective tax ratet | 23.1% |
| After-tax cost of debt | 3.13% |
| Equity weight$4.8B | 56.5% |
| Debt weight$3.7B | 43.5% |
| WACC | 5.95% |
Growth assumptions
Blended forward growth used as DCF default; terminal pegged to long-run nominal GDP.
| Analyst forward revenue growthFMP | 4.27% |
| Analyst forward EPS growthFMP | 63.50% |
| Historical 5y revenue CAGRFY | 1.54% |
| Historical 5y EPS CAGRFY | -7.41% |
| Sustainable g (ROE × retention)Δ | 8.30% |
| Blended near-term growth (g₀) | 25.00% |
| Terminal growth (gₗ) | 2.00% |
Sources
- FMP /analyst-estimates— 8 rows(as of 2022-12-27)
- Treasury rates · 10y— 4.46% rf(as of 2026-05-12)
- market_risk_premium · DB— 4.46% ERP(as of 2026-05-13)
- Sector multiple defaults— Healthcare (live sector PE unavailable)
- FMP /price-target-consensus— mean $86.43
This page is generated by a quantitative valuation engine for research purposes only and does not constitute investment advice. Methodology follows standard CFA / Damodaran frameworks; assumptions are driven by analyst consensus from Financial Modeling Prep and reported financial statements.